{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:59:05Z","timestamp":1792735145299,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005202","name":"Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005202","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000223","name":"Muscular Dystrophy Canada","doi-asserted-by":"publisher","award":["82016-4"],"award-info":[{"award-number":["82016-4"]}],"id":[{"id":"10.13039\/501100000223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009657","name":"FSHD Global Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009657","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010090","name":"Women and Children's Health Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012644","name":"Friends of FSH Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012644","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"publisher","award":["201810476"],"award-info":[{"award-number":["201810476"]}],"id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"publisher","award":["20170528"],"award-info":[{"award-number":["20170528"]}],"id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["143251"],"award-info":[{"award-number":["143251"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001805","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["30819"],"award-info":[{"award-number":["30819"]}],"id":[{"id":"10.13039\/501100001805","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009824","name":"FSH Society","doi-asserted-by":"publisher","award":["82018-2"],"award-info":[{"award-number":["82018-2"]}],"id":[{"id":"10.13039\/100009824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ymthe.2020.10.010","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T23:36:27Z","timestamp":1602718587000},"page":"848-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["DUX4 Transcript Knockdown with Antisense 2\u2032-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy"],"prefix":"10.1016","volume":"29","author":[{"given":"Kenji Rowel Q.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Echigoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia","family":"Dzierlega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.10.010_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11910-016-0667-0","article-title":"Facioscapulohumeral Dystrophy","volume":"16","author":"Wang","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.ymthe.2020.10.010_bib2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2020.10.010_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00439-011-1100-z","article-title":"Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled?","volume":"131","author":"Richards","year":"2012","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.10.010_bib4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.nmd.2006.06.008","article-title":"Severe phenotype in infantile facioscapulohumeral muscular dystrophy","volume":"16","author":"Klinge","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2020.10.010_bib5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archneur.1994.00540160085011","article-title":"Facioscapulohumeral muscular dystrophy in early childhood","volume":"51","author":"Brouwer","year":"1994","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymthe.2020.10.010_bib6","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.nmd.2017.09.007","article-title":"Early onset facioscapulohumeral dystrophy\u2014a systematic review using individual patient data","volume":"27","author":"Goselink","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2020.10.010_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5582\/irdr.2019.01016","article-title":"Management strategies in facioscapulohumeral muscular dystrophy","volume":"8","author":"Lu","year":"2019","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.ymthe.2020.10.010_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-1119(99)00267-X","article-title":"Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element","volume":"236","author":"Gabri\u00ebls","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2020.10.010_bib9","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.10.010_bib10","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/hmg\/3.8.1287","article-title":"Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy","volume":"3","author":"Hewitt","year":"1994","journal-title":"Hum. Mol. Genet."},{"issue":"R1","key":"10.1016\/j.ymthe.2020.10.010_bib11","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1093\/hmg\/ddv237","article-title":"Loss of epigenetic silencing of the DUX4 transcription factor gene in facioscapulohumeral muscular dystrophy","volume":"24","author":"Hewitt","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.10.010_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/hmg\/ddu486","article-title":"Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2","volume":"24","author":"Lemmers","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.10.010_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-genom-083118-014933","article-title":"The Genetics and Epigenetics of Facioscapulohumeral Muscular Dystrophy","volume":"20","author":"Himeda","year":"2019","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.ymthe.2020.10.010_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/ijms21030729","article-title":"DUX4 Signalling in the Pathogenesis of Facioscapulohumeral Muscular Dystrophy","volume":"21","author":"Lim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2020.10.010_bib15","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddw015","article-title":"Antisense targeting of 3\u2032 end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach","volume":"25","author":"Marsollier","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.10.010_bib16","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.10.010_bib17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/genes8030093","article-title":"Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)","volume":"8","author":"Ansseau","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2020.10.010_bib18","doi-asserted-by":"crossref","first-page":"e26820","DOI":"10.1371\/journal.pone.0026820","article-title":"The FSHD atrophic myotube phenotype is caused by DUX4 expression","volume":"6","author":"Vanderplanck","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2020.10.010_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2012.01647.x","article-title":"DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?","volume":"17","author":"Tassin","year":"2013","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.ymthe.2020.10.010_bib20","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1212\/NXG.0000000000000323","article-title":"Antisense oligonucleotides: A primer","volume":"5","author":"Scoles","year":"2019","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.ymthe.2020.10.010_bib21","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2020.10.010_bib22","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","article-title":"Volanesorsen: First Global Approval","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2020.10.010_bib23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.10.010_bib24","doi-asserted-by":"crossref","first-page":"e0192657","DOI":"10.1371\/journal.pone.0192657","article-title":"A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy","volume":"13","author":"Jones","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2020.10.010_bib25","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/hmg\/ddv315","article-title":"Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways","volume":"24","author":"Rickard","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.10.010_bib26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1582-4934.2008.00368.x","article-title":"Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects","volume":"14","author":"Barro","year":"2010","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.ymthe.2020.10.010_bib27","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/hmg\/ddy405","article-title":"Dynamic transcriptomic analysis reveals suppression of PGC1\u03b1\/ERR\u03b1 drives perturbed myogenesis in facioscapulohumeral muscular dystrophy","volume":"28","author":"Banerji","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.10.010_bib28","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.nmd.2007.04.002","article-title":"The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein","volume":"17","author":"Kowaljow","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymthe.2020.10.010_bib29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0006-2952(99)00412-8","article-title":"Inhibition of hypoxia\/reoxygenation-induced apoptosis by an antisense oligonucleotide targeted to JNK1 in human kidney cells","volume":"59","author":"Garay","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2020.10.010_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/mol.51.2.209","article-title":"Antisense oligonucleotides targeting human protein kinase C-alpha inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells","volume":"51","author":"Levesque","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ymthe.2020.10.010_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40262-014-0224-4","article-title":"Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(\u00ae)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B","volume":"54","author":"Geary","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ymthe.2020.10.010_bib32","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: First Global Approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ymthe.2020.10.010_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/genes8060161","article-title":"Splice-Switching Therapy for Spinal Muscular Atrophy","volume":"8","author":"Meijboom","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ymthe.2020.10.010_bib52","series-title":"Exon Skipping and Inclusion Therapies","first-page":"69","article-title":"Nusinersen in the treatment of spinal muscular atrophy","volume":"1828","author":"Goodkey","year":"2018"},{"key":"10.1016\/j.ymthe.2020.10.010_bib35","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/mt.2016.136","article-title":"Integrated Safety Assessment of 2\u2032-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers","volume":"24","author":"Crooke","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.10.010_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2018.0753","article-title":"Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2\u2032-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience","volume":"29","author":"Crooke","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2020.10.010_bib37","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.tcb.2007.02.004","article-title":"Barrier-to-autointegration factor\u2014a BAFfling little protein","volume":"17","author":"Margalit","year":"2007","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ymthe.2020.10.010_bib38","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1242\/jcs.083238","article-title":"Banf1 is required to maintain the self-renewal of both mouse and human embryonic stem cells","volume":"124","author":"Cox","year":"2011","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ymthe.2020.10.010_bib39","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1242\/jcs.180372","article-title":"DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis","volume":"129","author":"Knopp","year":"2016","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ymthe.2020.10.010_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.devcel.2011.11.013","article-title":"DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy","volume":"22","author":"Geng","year":"2012","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ymthe.2020.10.010_bib41","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1093\/hmg\/ddu251","article-title":"DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle","volume":"23","author":"Yao","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2020.10.010_bib42","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1038\/s41467-017-01200-4","article-title":"PAX7 target genes are globally repressed in facioscapulohumeral muscular dystrophy skeletal muscle","volume":"8","author":"Banerji","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.10.010_bib43","doi-asserted-by":"crossref","first-page":"113011","DOI":"10.1016\/j.expneurol.2019.113011","article-title":"Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy","volume":"320","author":"Mueller","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2020.10.010_bib44","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1038\/emboj.2008.201","article-title":"An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies","volume":"27","author":"Bosnakovski","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2020.10.010_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13395-020-00227-4","article-title":"Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity","volume":"10","author":"Jones","year":"2020","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2020.10.010_bib46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2044-5040-1-12","article-title":"Establishment of clonal myogenic cell lines from severely affected dystrophic muscles - CDK4 maintains the myogenic population","volume":"1","author":"Stadler","year":"2011","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.ymthe.2020.10.010_bib47","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.3390\/molecules20058304","article-title":"Culture Conditions Affect Expression of DUX4 in FSHD Myoblasts","volume":"20","author":"Pandey","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ymthe.2020.10.010_bib48","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nbt.3519","article-title":"Near-optimal probabilistic RNA-seq quantification","volume":"34","author":"Bray","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.10.010_bib49","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.ymthe.2020.10.010_bib50","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/gtc.12587","article-title":"Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences","volume":"23","author":"Yoshida","year":"2018","journal-title":"Genes Cells"},{"key":"10.1016\/j.ymthe.2020.10.010_bib51","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1242\/bio.20121305","article-title":"Conditional over-expression of PITX1 causes skeletal muscle dystrophy in mice","volume":"1","author":"Pandey","year":"2012","journal-title":"Biol. Open"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162030544X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162030544X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:51:36Z","timestamp":1778521896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162030544X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S152500162030544X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.10.010","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DUX4 Transcript Knockdown with Antisense 2\u2032-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}